Agnieszka Stelmaszyk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Agnieszka Stelmaszyk has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Marzena Dworacka
Department of Pharmacology, Poznan University of Medical Sciences, Poznan, Poland
6 shared publications - Anna Wesołowska
Department of Pharmacology, Poznan University of Medical Sciences, Rokietnicka 5d, 60-805 Poznań, Poland
2 shared publications - Bartosz Adam Frycz
Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Święcickiego 6, 60-781 Poznań, Poland
2 shared publications - Saule Iskakova
Department of Pharmacology, Asfendiyarov Kazakh National Medical University, Tole Bi Str. 94, Almaty 050000, Kazakhstan
2 shared publications - Anna Maliszewska-Dworacka1 shared publication
Anna Wesołowska
Department of Pharmacology, Poznan University of Medical Sciences, Rokietnicka str. 5a, 60-805 Poznań, Poland
1 shared publication
Latest Publications
- Open Access
- 29 December 2025
- Published by Poznan University of Medical Sciences in Journal of Medical Science
- Vol. 94 (4)
Passiflora incarnata extract-induced VEGF and TGF-β1 mRNA expression in the cardiovascular system using the rat model of type 2 diabetes
Aim. To investigate the possible effects of Passiflora extract on VEGF and TGF-β1 mRNA expression – growth factors closely related to the development of diabetes in the cardiovascular system. Material and methods. The animal model of type 2 diabetes, rich-fat/STZ Wistar rats, was used. Animals were randomised into four groups: Passiflora-treated type 2 diabetes mellitus model group; metformin-treated type 2 diabetes mellitus model group; placebo-treated type 2 diabetes mellitus model group; and placebo-treated non-diabetic control group. Passiflora incarnata leaf extract was administered orally once daily for eight consecutive weeks. mRNA VEGF, VEGF-R1, VEGF-R2 and TGF-β1 expression were measured in the myocardium and the aorta. Results. Passiflora incarnata extract increases VEGF and VEGFR2 mRNA expression in the myocardium of rats with type 2 diabetes and decreases expression in the aortal wall. The expression of TGF-β1 mRNA in both the myocardium and the aorta is reduced in Passiflora incarnata-treated rats with diabetes. Most observed effects are independent of the animals' current metabolic status. Conclusions. The current data provide novel findings on the beneficial effects of Passiflora extract on the myocardium in the context of type 2 diabetes, potentially through mechanisms involving VEGF and TGF-β1. However, the significance of the impact of Passiflora extract on the aorta wall via VEGF and TGF-β1 is uncertain.
- 29 December 2025
- Published by Poznan University of Medical Sciences in Journal of Medical Science
- Vol. 94 (4)
Open AccessPassiflora incarnata extract-induced VEGF and TGF-β1 mRNA expression in the cardiovascular system using the rat model of type 2 diabetes
Aim. To investigate the possible effects of Passiflora extract on VEGF and TGF-β1 mRNA expression – growth factors closely related to the development of diabetes in the cardiovascular system. Material and methods. The animal model of type 2 diabetes, rich-fat/STZ Wistar rats, was used. Animals were randomised into four groups: Passiflora-treated type 2 diabetes mellitus model group; metformin-treated type 2 diabetes mellitus model group; placebo-treated type 2 diabetes mellitus model group; and placebo-treated non-diabetic control group. Passiflora incarnata leaf extract was administered orally once daily for eight consecutive weeks. mRNA VEGF, VEGF-R1, VEGF-R2 and TGF-β1 expression were measured in the myocardium and the aorta. Results. Passiflora incarnata extract increases VEGF and VEGFR2 mRNA expression in the myocardium of rats with type 2 diabetes and decreases expression in the aortal wall. The expression of TGF-β1 mRNA in both the myocardium and the aorta is reduced in Passiflora incarnata-treated rats with diabetes. Most observed effects are independent of the animals' current metabolic status. Conclusions. The current data provide novel findings on the beneficial effects of Passiflora extract on the myocardium in the context of type 2 diabetes, potentially through mechanisms involving VEGF and TGF-β1. However, the significance of the impact of Passiflora extract on the aorta wall via VEGF and TGF-β1 is uncertain.
- 1 September 2021
- Published by Elsevier in European Journal of Pharmacology
- Vol. 907, 174289
Sirtuin 1 as the mechanism of action of agents used in the diabetes mellitus pharmacotherapy
- 1 September 2021
- Published by Elsevier in European Journal of Pharmacology
- Vol. 907, 174289
Sirtuin 1 as the mechanism of action of agents used in the diabetes mellitus pharmacotherapy
- 1 September 2018
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 143, 245-253
Simvastatin attenuates the aberrant expression of angiogenic factors induced by glucose variability
- 1 September 2018
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 143, 245-253
Simvastatin attenuates the aberrant expression of angiogenic factors induced by glucose variability
- Open Access
- 20 July 2018
- Published by Springer Nature in Saudi Pharmaceutical Journal
- Vol. 26 (8) , 1192-1198
The impact of dapagliflozin on glucose excursions related to early proatherogenic derangement in the aortic wall
Introduction: Cardiovascular risk in the course of diabetes depends greatly on glycemic variability which is even more significant than chronic hyperglycemia. Optimal management of diabetes involves a multidisciplinary approach focused in particular on decreasing the risk of atherosclerosis. Therefore, our purpose was to evaluate the impact of dapagliflozin on glucose excursions and related proatherogenic changes in the aortic wall. Methods and materials Animal model of type 2 diabetes rich-fat/STZ rats was used. Wistar rats were randomized into 3 groups: dapagliflozin-treated with glucose excursions, placebo-treated with glucose excursions and placebo-treated with stable diabetes. Dapagliflozin was administered once a day, 1 mg/kg, for 8 consecutive weeks. Glucose levels were measured twice a week at fasting and postprandially. The samples of aortas were taken for histopathological and immunochemistry examinations at the end of the experiment. The derangement in the aortic wall and the distribution of CD68+ cells in the aorta were considered early signs of atherosclerosis. Results: Dapagliflozin reduced glucose excursion to the level characteristic for stable, well-controlled diabetes. It was related to a significant decrease in histopathological changes which were observed in the placebo-treated rats with glucose variability. Dapagliflozin significantly reduced also the accumulation of CD68+ macrophages in the aortic adventitia. Conclusion: Dapagliflozin provides not only mere beneficial regulation of metabolic status with the depletion of glucose variability, but is also helpful in the prevention of early atherosclerosis related to the course of diabetes type 2.
- 20 July 2018
- Published by Springer Nature in Saudi Pharmaceutical Journal
- Vol. 26 (8) , 1192-1198
Open AccessThe impact of dapagliflozin on glucose excursions related to early proatherogenic derangement in the aortic wall
Introduction: Cardiovascular risk in the course of diabetes depends greatly on glycemic variability which is even more significant than chronic hyperglycemia. Optimal management of diabetes involves a multidisciplinary approach focused in particular on decreasing the risk of atherosclerosis. Therefore, our purpose was to evaluate the impact of dapagliflozin on glucose excursions and related proatherogenic changes in the aortic wall. Methods and materials Animal model of type 2 diabetes rich-fat/STZ rats was used. Wistar rats were randomized into 3 groups: dapagliflozin-treated with glucose excursions, placebo-treated with glucose excursions and placebo-treated with stable diabetes. Dapagliflozin was administered once a day, 1 mg/kg, for 8 consecutive weeks. Glucose levels were measured twice a week at fasting and postprandially. The samples of aortas were taken for histopathological and immunochemistry examinations at the end of the experiment. The derangement in the aortic wall and the distribution of CD68+ cells in the aorta were considered early signs of atherosclerosis. Results: Dapagliflozin reduced glucose excursion to the level characteristic for stable, well-controlled diabetes. It was related to a significant decrease in histopathological changes which were observed in the placebo-treated rats with glucose variability. Dapagliflozin significantly reduced also the accumulation of CD68+ macrophages in the aortic adventitia. Conclusion: Dapagliflozin provides not only mere beneficial regulation of metabolic status with the depletion of glucose variability, but is also helpful in the prevention of early atherosclerosis related to the course of diabetes type 2.
- Open Access
- 21 May 2018
- Published by VM Media Group sp. z o.o in Clinical Diabetology
- Vol. 7 (3) , 164-170
The importance of epigenetic factors for the diagnostics and treatment of type 2 diabetes mellitus
The level of expression of certain genes modifying the phenotype may affect the progression of diabetes mellitus and its complications. Gene expression is controlled by epigenetic modifications, influenced by intracellular and environmental factors, e.g. nutrition model and physical activity. These modifications appear throughout whole life, from conception until the time of death, and they are closely dependent on cell differentiation, DNA repair and cellular stress. Hopefully, the knowledge of epigenetics might be used in the future as an element of personalized treatment of diabetes. The following article aims to review the most important mechanisms of epigenetic modifications in context of pathogenesis and pathophysiology of type 2 diabetes mellitus. The level of expression of certain genes modifying the phenotype may affect the progression of diabetes mellitus and its complications. Gene expression is controlled by epigenetic modifications, influenced by intracellular and environmental factors, e.g. nutrition model and physical activity. These modifications appear throughout whole life, from conception until the time of death, and they are closely dependent on cell differentiation, DNA repair and cellular stress. Hopefully, the knowledge of epigenetics might be used in the future as an element of personalized treatment of diabetes. The following article aims to review the most important mechanisms of epigenetic modifications in context of pathogenesis and pathophysiology of type 2 diabetes mellitus.
- 21 May 2018
- Published by VM Media Group sp. z o.o in Clinical Diabetology
- Vol. 7 (3) , 164-170
Open AccessThe importance of epigenetic factors for the diagnostics and treatment of type 2 diabetes mellitus
The level of expression of certain genes modifying the phenotype may affect the progression of diabetes mellitus and its complications. Gene expression is controlled by epigenetic modifications, influenced by intracellular and environmental factors, e.g. nutrition model and physical activity. These modifications appear throughout whole life, from conception until the time of death, and they are closely dependent on cell differentiation, DNA repair and cellular stress. Hopefully, the knowledge of epigenetics might be used in the future as an element of personalized treatment of diabetes. The following article aims to review the most important mechanisms of epigenetic modifications in context of pathogenesis and pathophysiology of type 2 diabetes mellitus. The level of expression of certain genes modifying the phenotype may affect the progression of diabetes mellitus and its complications. Gene expression is controlled by epigenetic modifications, influenced by intracellular and environmental factors, e.g. nutrition model and physical activity. These modifications appear throughout whole life, from conception until the time of death, and they are closely dependent on cell differentiation, DNA repair and cellular stress. Hopefully, the knowledge of epigenetics might be used in the future as an element of personalized treatment of diabetes. The following article aims to review the most important mechanisms of epigenetic modifications in context of pathogenesis and pathophysiology of type 2 diabetes mellitus.
- Open Access
- 17 November 2017
- Published by VM Media Group sp. z o.o in Clinical Diabetology
- Vol. 6 (4) , 142-146
The impact of dapagliflozin on cardiovascular system in the course of type 2 diabetes mellitus
The following paper is an attempt to revise current data and the results of clinical trials concerning the impact of dapagliflozin on long-term cardiovascular complications of type 2 diabetes mellitus. Short-term clinical trials, including relatively small groups of patients, suggest positive influence of dapagliflozin on the cardiovascular system. Currently ongoing long-term trials are likely to confirm these data, but so far we can assume that dapagliflozin not only acts as an efficient antihyperglycaemic drug, but also protects the circulatory system in patients with type 2 diabetes mellitus. The following paper is an attempt to revise current data and the results of clinical trials concerning the impact of dapagliflozin on long-term cardiovascular complications of type 2 diabetes mellitus. Short-term clinical trials, including relatively small groups of patients, suggest positive influence of dapagliflozin on the cardiovascular system. Currently ongoing long-term trials are likely to confirm these data, but so far we can assume that dapagliflozin not only acts as an efficient antihyperglycaemic drug, but also protects the circulatory system in patients with type 2 diabetes mellitus.
- 17 November 2017
- Published by VM Media Group sp. z o.o in Clinical Diabetology
- Vol. 6 (4) , 142-146
Open AccessThe impact of dapagliflozin on cardiovascular system in the course of type 2 diabetes mellitus
The following paper is an attempt to revise current data and the results of clinical trials concerning the impact of dapagliflozin on long-term cardiovascular complications of type 2 diabetes mellitus. Short-term clinical trials, including relatively small groups of patients, suggest positive influence of dapagliflozin on the cardiovascular system. Currently ongoing long-term trials are likely to confirm these data, but so far we can assume that dapagliflozin not only acts as an efficient antihyperglycaemic drug, but also protects the circulatory system in patients with type 2 diabetes mellitus. The following paper is an attempt to revise current data and the results of clinical trials concerning the impact of dapagliflozin on long-term cardiovascular complications of type 2 diabetes mellitus. Short-term clinical trials, including relatively small groups of patients, suggest positive influence of dapagliflozin on the cardiovascular system. Currently ongoing long-term trials are likely to confirm these data, but so far we can assume that dapagliflozin not only acts as an efficient antihyperglycaemic drug, but also protects the circulatory system in patients with type 2 diabetes mellitus.
- 1 September 2015
- Published by Springer Nature in Pharmacological Reports
- Vol. 67, 43
Dapagliflozin decreases glycaemic variability and peripheral insulin resistance in rats with diabetes
- 1 September 2015
- Published by Springer Nature in Pharmacological Reports
- Vol. 67, 43
Dapagliflozin decreases glycaemic variability and peripheral insulin resistance in rats with diabetes